Trials / Completed
CompletedNCT04298879
IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3Kδ Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
Detailed description
Patients will be recruited for 2 cohorts. Cohort A will recruit 58 RRFL subjects, and Cohort B will recruit 62 RRMZL subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI376 | IBI376 20 mg po. once daily for 8 weeks ，followed by 2.5mg once daily |
Timeline
- Start date
- 2020-04-07
- Primary completion
- 2021-07-27
- Completion
- 2023-11-21
- First posted
- 2020-03-06
- Last updated
- 2024-06-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04298879. Inclusion in this directory is not an endorsement.